アレルギー性結膜炎の世界市場、規模とシェアの分析 - 成長動向、予測（2025年～2033年）

世界のアレルギー性結膜炎の市場規模

世界のアレルギー性結膜炎の市場規模は、2024年の20億米ドルから2033年までに24億6,000万米ドルに達すると予測され、2025年～2033年にCAGRで2.31%の成長が見込まれます。アレルギーの罹患率の増加、環境汚染、気候変動、利用可能な治療法に関する知識の増加が、アレルギー性結膜炎市場の主な促進要因です。市場が拡大しているのは、コルチコステロイドや抗ヒスタミン薬などの薬物療法の開発が進んでいるためです。

アレルギー性結膜炎市場の成長促進要因

アレルギーの有病率の上昇

アレルギー性結膜炎市場の主な促進要因の1つは、世界のアレルギー患者の増加です。カビ、ダニ、花粉、ペットのフケなどによる季節性・環境性アレルギーの増加により、アレルギー性結膜炎にかかる人が増えています。目の充血、かゆみ、涙目は、特定のアレルギーによって引き起こされる目の炎症の兆候です。このようなアレルギーの影響を受ける人が増えるにつれ、効率的な治療法へのニーズが高まっています。抗ヒスタミン薬、点眼薬などの治療薬の市場は、特に都市部で、大人にも子供にもアレルギーが流行しているため、成長しています。この疾患に関する知識の増加により、治療を求める行動が増加した結果、市場は拡大しています。

気候変動と環境汚染

アレルギー性結膜炎などのアレルギー症状は、気候変動と環境汚染の増加により大きく悪化しています。都市化、気温上昇、オゾンや粒子状物質のような大気汚染物質の濃度の上昇により、花粉のようなアレルゲンにさらされる機会が増えています。空気中のアレルゲン濃度が高くなり、花粉症の季節が長くなると、アレルギー性結膜炎の症状が悪化し、治療の必要性が高まります。さらに、植物種やアレルゲンの分布は気候変動の影響を受け、季節性アレルギーが発生する地域が拡大しています。環境刺激にさらされる機会が増えた結果、アレルギー性結膜炎の症状を軽減する治療市場が拡大しています。

治療オプションの進歩

アレルギー性結膜炎の治療オプションの改良により、市場は拡大し、患者の治療成績は大きく向上しました。コルチコステロイド、肥満細胞安定化薬、抗ヒスタミン薬などの新しく改良された薬剤の開発により、患者はより具体的かつ効率的に症状を管理できるようになっています。アレルギー注射や舌下錠のような免疫療法の進歩は、アレルギーの根本的な原因を治療することで、従来の治療に加えて、より長期的な緩和をもたらします。急性増悪の頻度や強さを軽減することで、これらの医薬品はアレルギー性結膜炎の管理に革命をもたらしています。利用可能な医薬品の範囲が広がったおかげで、患者の要望に合った選択肢が増え、短期的・長期的な治療薬の両方が広く利用されるようになり、アレルギー性結膜炎の市場はさらに拡大しています。

アレルギー性結膜炎市場の課題

重症例に対する限られた選択肢

業界における大きな問題は、重症のアレルギー性結膜炎に対する選択肢が少ないことです。抗ヒスタミン薬や肥満細胞安定化薬は、中等度のアレルギー性結膜炎に対しては一般的な治療法ですが、重症例に対しては有効でないことが多いです。状況によっては、コルチコステロイドを含むより積極的な治療が勧められることもあります。しかし、コルチコステロイドは眼圧の上昇や白内障の形成など、長期間の使用に伴う潜在的な危険性があるため、長期間の治療には適していません。重症または難治性のアレルギー性結膜炎に対する適切な治療法が少ないため、患者のかなりの部分が適切な治療を受けることができません。そのため、長期的な悪影響を引き起こすことなく、重症例を安全かつ効果的に治療できる新しい治療法の必要性が高まっています。

当レポートでは、世界のアレルギー性結膜炎市場について調査し、成長促進要因と課題、各セグメントの分析、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査と調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 世界のアレルギー性結膜炎市場

第6章 世界のアレルギー性結膜炎の市場シェア分析

• 疾患タイプ別
• 薬剤クラス別
• 流通チャネル別
• 国別

第7章 疾患タイプ

• 季節性アレルギー性結膜炎（SAC）
• 通年性アレルギー性結膜炎（PAC）

第8章 薬剤クラス

• 抗ヒスタミン薬・肥満細胞安定薬
• コルチコステロイド
• その他

第9章 流通チャネル

• 病院薬局
• オンライン薬局
• 小売薬局・ドラッグストア
• その他

第10章 国

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
  • トルコ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 ポーターのファイブフォース分析

第12章 SWOT分析

第13章 主要企業の分析

• Ajanta Pharma Limited
• Alembic Pharmaceutical Ltd.
• Cipla Inc.
• Indoco Remedies Ltd.
• Johnson & Johnson
• Novartis AG
• Ocular Therapeutix, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Global Allergic Conjunctivitis Market Size

Allergic Conjunctivitis market is expected to reach US$ 2.46 billion by 2033 from US$ 2.00 in 2024, with a CAGR of 2.31% from 2025 to 2033. The growing incidence of allergies, environmental contamination, climate change, and growing knowledge of available treatments are the main factors driving the allergic conjunctivitis market. The market is expanding because to developments in medication therapy, such as corticosteroids and antihistamines.

Allergic Conjunctivitis Market Global Report by Disease Types (Seasonal ALLERGIC Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC)), Drugs Class (Antihistamines & Mast Cell Stabilizers, Corticosteroids, Others), Distribution Channels (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies & Drug Stores, Others), Countries and Company Analysis 2025-2033

Allergic Conjunctivitis Industry Overview

Environmental pollution, rising awareness of eye care, and the growing frequency of allergies worldwide have all contributed to the steady rise of the allergic conjunctivitis sector. Common symptoms of allergic conjunctivitis include itching, redness, and watery eyes. It is brought on by allergens including mold, dust mites, pollen, or pet dander. The increasing need for therapies has been greatly influenced by the growing prevalence of allergic reactions, especially seasonal allergies. In addition, elements like air pollution, urbanization, and climate change are making allergy conditions worse, which is why more individuals are turning to prescription and over-the-counter treatments for relief. Growing public knowledge of the illness and available treatments is another factor supporting this trend, which is anticipated to further expand the market.

Treatment innovations such as mast cell stabilizers, corticosteroids, and antihistamines have been crucial in propelling market expansion. Furthermore, immunotherapy advancements like allergy shots and sublingual pills are giving patients longer-lasting relief, which is fueling the market's growth. Patients now have greater access to symptom treatment because to the availability of eye drops and both prescription and over-the-counter alternatives. The industry for allergic conjunctivitis is expected to grow as the prevalence of allergies increases worldwide. This growth will be aided by consumer education, further research into better therapies, and the increased focus on eye health in general healthcare. With ongoing product advancements and a growing array of patient therapy, this industry is predicted to stay vibrant.

The American Academy of Allergy, Asthma & Immunology estimates that approximately 100 million Americans experienced some form of allergy in 2022. The approaching robust pipeline of medications shows that major pharmaceutical companies are putting more emphasis on the research and development (R&D) of effective therapies as a result of the disease's rising prevalence. Aldeyra Therapeutics, Inc., for example, revealed the phase 3 findings of the INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution for allergic conjunctivitis in June 2023. These advancements will accelerate the market expansion for allergic conjunctivitis in the near future.

Growth Drivers for the Allergic Conjunctivitis Market

Rising Prevalence of Allergies

One of the main factors propelling the market for allergic conjunctivitis is the increase in allergy cases worldwide. More people are suffering from allergic conjunctivitis as a result of rising rates of seasonal and environmental allergies, including those brought on by mold, dust mites, pollen, and pet dander. Redness, itching, and watery eyes are signs of eye inflammation brought on by certain allergies. The need for efficient therapies has increased as more people are impacted by these allergies. The market for antihistamines, eye drops, and other treatments is growing as allergies are becoming more prevalent in both adults and children, especially in cities. The market is growing as a result of increased treatment-seeking behaviors brought on by growing knowledge of the ailment.

Climate Change and Environmental Pollution

Allergy symptoms, such as allergic conjunctivitis, are becoming considerably worse due to climate change and increased environmental pollution. Exposure to allergens like pollen has increased due to urbanization, temperature rise, and increased concentrations of airborne pollutants like ozone and particulate matter. Higher airborne allergen concentrations and longer pollen seasons exacerbate allergic conjunctivitis symptoms, increasing the requirement for treatment. Furthermore, the distribution of plant species and allergens is impacted by climate change, expanding the geographic regions in which seasonal allergies are experienced. The market for treatments that can reduce symptoms of allergic conjunctivitis is expanding as a result of the increased exposure to environmental stimuli.

Advancements in Treatment Options:

The market has grown and patient outcomes have been greatly improved by improvements in treatment choices for allergic conjunctivitis. Patients now have more specific and efficient ways to manage their symptoms because to the development of new and improved medications such corticosteroids, mast cell stabilizers, and antihistamines. By treating the underlying cause of allergies, immunotherapy advances like allergy injections and sublingual pills provide longer-lasting relief in addition to conventional therapies. By lessening the frequency and intensity of flare-ups, these medicines are revolutionizing the management of allergic conjunctivitis. Patients now have more alternatives that are suited to their demands thanks to the expanding spectrum of available medicines, which is propelling the market for allergic conjunctivitis to rise further as both short-term and long-term remedies become more widely available.

Challenges in the Allergic Conjunctivitis Market

Limited Options for Severe Cases

A major problem in the industry is the lack of choices for severe allergic conjunctivitis. Antihistamines and mast cell stabilizers are common treatments for moderate cases of allergic conjunctivitis, but they frequently don't work effectively for people with severe cases. More aggressive therapies, including corticosteroids, might be recommended in certain situations. However, corticosteroids are not appropriate for long-term therapy due to the potential hazards associated with extended use, such as elevated intraocular pressure and cataract formation. A significant portion of patients cannot receive appropriate treatments due to the dearth of adequate therapeutic alternatives for severe or refractory allergic conjunctivitis. New treatments that may safely and effectively treat severe cases without causing long-term negative effects are therefore becoming more and more necessary.

Cost of Advanced Treatments

One of the biggest obstacles to accessibility in the market for allergic conjunctivitis is the high cost of sophisticated therapies like immunotherapy (allergy injections or sublingual pills). Although these treatments address the underlying cause of the illness and offer long-term relief, their cost prevents a larger population from using them. Immunotherapy frequently necessitates multiple treatments spread out over months or even years, which raises the total cost even more. These treatments could be unaffordable for people who live in low-income areas or don't have health insurance. Because of this, a lot of patients still use less effective but more reasonably priced over-the-counter drugs. This discrepancy in access to therapy emphasizes the need for more equitable healthcare and affordable ways to treat allergic conjunctivitis.

Allergic Conjunctivitis Market Overview by Regions

By countries, the global Allergic Conjunctivitis market is divided into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia and UAE.

United States Allergic Conjunctivitis Market

The rising incidence of allergies, particularly seasonal and environmental allergens including dust, pollen, and pet dander, is driving growth in the US market for allergic conjunctivitis. The need for efficient therapies has increased since allergic conjunctivitis affects about 20% of Americans. Treatment developments such corticosteroids, mast cell stabilizers, and antihistamines have improved patient outcomes. Furthermore, the market is expanding because to the advent of immunotherapy treatments like allergy injections and sublingual pills, which provide long-term relief. However, obstacles including the expensive price of cutting-edge therapies and their adverse effects could prevent the industry from growing more widely. Nevertheless, it is anticipated that the industry will continue to be driven by rising awareness, easier access to healthcare, and the continuous development of innovative treatments.

Germany Allergic Conjunctivitis Market

The increasing incidence of allergies brought on by dust, pollen, and pet dander is driving growth in the German market for allergic conjunctivitis. With millions of cases of allergic conjunctivitis each year, Germany, a major market in Europe, is experiencing an increase in demand for efficient treatments. Patient outcomes have greatly improved with the availability of antihistamines, corticosteroids, mast cell stabilizers, and more sophisticated immunotherapies such allergy injections and sublingual tablets. The market is growing as a result of improved access to healthcare and treatment choices, as well as growing awareness of allergic conjunctivitis. But issues like exorbitant medical expenses and few choices for serious situations still exist. Nevertheless, the industry is anticipated to continue growing due to Germany's robust healthcare system and emphasis on innovation.

China Allergic Conjunctivitis Market

The market for allergic conjunctivitis is expanding significantly in China as a result of the rising incidence of allergies brought on by urbanization, pollution, and climate change. The prevalence of allergic reactions, particularly allergic conjunctivitis, has increased due to rising air pollution levels, pollen, and dust. As more people look for solutions to symptoms including eye watering, redness, and itching, the need for efficient treatments is growing. The market is growing as a result of improvements in treatment alternatives, such as immunotherapy, corticosteroids, and antihistamines. However, obstacles including low knowledge of the illness, particularly in rural regions, and the high cost of cutting-edge treatments could prevent wider market access. Despite this, the industry is anticipated to rise in the upcoming years due to expanding healthcare infrastructure and easier access to medications.

Saudi Arabia Allergic Conjunctivitis Market

The market for allergic conjunctivitis is expanding in Saudi Arabia as a result of the rising incidence of allergies, which are made worse by regionally prevalent environmental variables like dust storms, air pollution, and high pollen counts. These elements play a part in the increase in occurrences of allergic conjunctivitis, especially in cities. As more people look for relief from symptoms including eye irritation, redness, and watering, there is an increasing need for efficient therapies like antihistamines, corticosteroids, and immunotherapy (allergy injections and sublingual pills). Improvements in healthcare infrastructure and an increasing emphasis on eye health are anticipated to propel market expansion in Saudi Arabia, increasing access to treatments despite obstacles such low awareness in rural areas and the high cost of modern therapies.

Allergic Conjunctivitis Market Segments

Disease Types

1. Seasonal ALLERGIC Conjunctivitis (SAC)

2. Perennial Allergic Conjunctivitis (PAC)

Drugs Class

1. Antihistamines & Mast Cell Stabilizers

2. Corticosteroids

3. Others

Distribution Channels

1. Hospital Pharmacies

2. Online Pharmacies

3. Retail Pharmacies & Drug Stores

4. Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE

All the Key players have been covered from 5 Viewpoints:

• Overview
• Key Person
• Product Analysis
• Recent Development
• Revenue

Key Players Analysis

1. Ajanta Pharma Limited

2. Akorn Operating Company LLC

3. Alembic Pharmaceutical Ltd.

4. Cipla Inc.

5. Indoco Remedies Ltd.

6. Johnson & Johnson

7. Novartis AG

8. Ocular Therapeutix, Inc.

9. Sun Pharmaceutical Industries Ltd.

10. Teva Pharmaceutical Industries Ltd

Key Questions Answered in Report:

1. How big is the Allergic Conjunctivitis industry?

The global Allergic Conjunctivitis market size was valued at US$ 2.00 billion in 2024 and is expected to reach US$ 2.46 billion in 2033.

2. What is the Allergic Conjunctivitis growth rate?

The global Allergic Conjunctivitis market is expected to expand at a compound annual growth rate (CAGR) of 2.31% from 2025 to 2033.

3. Who are the key players in Allergic Conjunctivitis industry?

Some key players operating in the Allergic Conjunctivitis market includes Ajanta Pharma Limited, Akorn Operating Company LLC, Alembic Pharmaceutical Ltd., Cipla Inc., Indoco Remedies Ltd., Johnson & Johnson, Novartis AG, Ocular Therapeutix, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd.

4. What are the factors driving the Allergic Conjunctivitis industry?

Growing environmental pollution, increased exposure to allergens, increased awareness, improved treatment options, and the growing incidence of allergies worldwide are some of the factors propelling the allergic conjunctivitis market.

5. Which Region held the largest market share in the Allergic Conjunctivitis industry?

North America is expected to hold the largest market share in the industry.

6. What segments are covered in the Allergic Conjunctivitis Market report?

Disease Types, Drugs Class, Distribution Channels and Countries segment are covered in this report.

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Global Allergic Conjunctivitis Market

6. Global Allergic Conjunctivitis Market Share Analysis

• 6.1 By Disease Types
• 6.2 By Drugs Class
• 6.3 By Distribution Channels
• 6.4 By Country

7. Disease Types

• 7.1 Seasonal ALLERGIC Conjunctivitis (SAC)
• 7.2 Perennial Allergic Conjunctivitis (PAC)

8. Drugs Class

• 8.1 Antihistamines & Mast Cell Stabilizers
• 8.2 Corticosteroids
• 8.3 Others

9. Distribution Channels

• 9.1 Hospital Pharmacies
• 9.2 Online Pharmacies
• 9.3 Retail Pharmacies & Drug Stores
• 9.4 Others

10. Countries

• 10.1 North America
  • 10.1.1 United States
  • 10.1.2 Canada
• 10.2 Europe
  • 10.2.1 France
  • 10.2.2 Germany
  • 10.2.3 Italy
  • 10.2.4 Spain
  • 10.2.5 United Kingdom
  • 10.2.6 Belgium
  • 10.2.7 Netherlands
  • 10.2.8 Turkey
• 10.3 Asia Pacific
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 Australia
  • 10.3.5 South Korea
  • 10.3.6 Thailand
  • 10.3.7 Malaysia
  • 10.3.8 Indonesia
  • 10.3.9 New Zealand
• 10.4 Latin America
  • 10.4.1 Brazil
  • 10.4.2 Mexico
  • 10.4.3 Argentina
• 10.5 Middle East & Africa
  • 10.5.1 South Africa
  • 10.5.2 Saudi Arabia
  • 10.5.3 United Arab Emirates

11. Porter's Five Forces Analysis

• 11.1 Bargaining Power of Buyers
• 11.2 Bargaining Power of Suppliers
• 11.3 Degree of Competition
• 11.4 Threat of New Entrants
• 11.5 Threat of Substitutes

12. SWOT Analysis

• 12.1 Strength
• 12.2 Weakness
• 12.3 Opportunity
• 12.4 Threats

13. Key Players Analysis

• 13.1 Ajanta Pharma Limited
  • 13.1.1 Overview
  • 13.1.2 Key Person
  • 13.1.3 Recent Developments
  • 13.1.4 Revenue
• 13.2 Akorn Operating Company LLC
  • 13.2.1 Overview
  • 13.2.2 Key Person
  • 13.2.3 Recent Developments
  • 13.2.4 Revenue
• 13.3 Alembic Pharmaceutical Ltd.
  • 13.3.1 Overview
  • 13.3.2 Key Person
  • 13.3.3 Recent Developments
  • 13.3.4 Revenue
• 13.4 Cipla Inc.
  • 13.4.1 Overview
  • 13.4.2 Key Person
  • 13.4.3 Recent Developments
  • 13.4.4 Revenue
• 13.5 Indoco Remedies Ltd.
  • 13.5.1 Overview
  • 13.5.2 Key Person
  • 13.5.3 Recent Developments
  • 13.5.4 Revenue
• 13.6 Johnson & Johnson
  • 13.6.1 Overview
  • 13.6.2 Key Person
  • 13.6.3 Recent Developments
  • 13.6.4 Revenue
• 13.7 Novartis AG
  • 13.7.1 Overview
  • 13.7.2 Key Person
  • 13.7.3 Recent Developments
  • 13.7.4 Revenue
• 13.8 Ocular Therapeutix, Inc.
  • 13.8.1 Overview
  • 13.8.2 Key Person
  • 13.8.3 Recent Developments
  • 13.8.4 Revenue
• 13.9 Sun Pharmaceutical Industries Ltd.
  • 13.9.1 Overview
  • 13.9.2 Key Person
  • 13.9.3 Recent Developments
  • 13.9.4 Revenue
• 13.10 Teva Pharmaceutical Industries Ltd.
  • 13.10.1 Overview
  • 13.10.2 Key Person
  • 13.10.3 Recent Developments
  • 13.10.4 Revenue